Category: Pharmaceuticals
Fulcrum plans to initiate a Phase 2b clinical trial in mid-2019 on patients with FSHD in the U.S. and Europe. Fulcrum Therapeutics, a biotechnology firm focused on discovering and developing therapies to rebalance gene expression, has recently announced its exclusive global license agreement with British …
The company now possesses over 91 ANDA approvals, approximately 79 final approvals & 12 tentative approvals, from the FDA. Company shares went up by 1% following the FDA approval of the Teriflunomide tablets. Alembic Pharmaceuticals Ltd (Alembic), a renowned Indian multinational pharmaceutical company, has reportedly …
The new drug would be sold under the brand name Hemlibra in the country It represents an entirely new way to manage Hemophilia A and reviews the standard of care Roche Pharmaceuticals, the Swiss multinational healthcare company, has reportedly announced that it has introduced Emicizumab …
The trial would be funded entirely by MediciNova The result of a successful pivotal trial would lead to the Phase 2b/3 efficacy and safety data support a New Drug Application (NDA) MediciNova, Inc., a biopharmaceutical firm, has reportedly announced that the U.S. Food and Drug …
The portfolio in question includes over 30 generic injectable products. The latest acquisition expands Dr. Reddy’s current portfolio by a considerable margin. Dr. Reddy’s Laboratories Ltd., (Dr. Reddy’s), a renowned Indian multinational pharmaceutical firm based out of Hyderabad, has reportedly entered into a definitive agreement …
AstraZeneca and U.S. partner MSD Inc. have made it to the headlines for winning European Commission’s approval for Lynparza (olaparib), their blockbuster candidate originated and developed in Cambridge for the treatment of breast Cancer. As per trusted sources, the candidate has been backed by the …
One of the world’s leading pharma company GlaxoSmithKline Plc has reportedly attained the approval of the U.S. FDA for marketing its two-drug treatment for HIV infections, thereby boosting its growth prospects against rival Gilead Sciences Inc. As per trusted sources, the U.S. FDA cleared Dovato, …
The clinical-stage biotechnology company, Aeglea BioTherapeutics Inc., has reportedly announced positive Phase 1/2 data for Pegzilarginase to be used in the treatment of patients with ARG1-D (Arginase 1 Deficiency). Dr. George Diaz, Ph.D., M.D., Division Chief of Medical Genetics, Icahn School of Medicine, New York, …
Clinical-stage biopharmaceutical company Viking Therapeutics, Inc. will reportedly present data from its 12-week long Phase 2 trial of VK2809 on individuals suffering from non-alcoholic fatty liver disease and elevated low-density lipoprotein cholesterol at the International Liver Congress™ 2019. According to familiar sources, the study results …
